National Pain Care Policy Act of 2009

S.27 - Preserve Access to Affordable Generics Act S.301 - Physician Payments Sunshine Act of 2009 S.319 - Pharmaceutical Market Access and Drug Safety Act of 2011 H.R.1191/S.1336 - Safe Drug Disposal Act of 2009 H.R.1260/S.515 & 610 - Patent Reform Act of 2009 H.R.1298/S.525 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 - Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 - Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 - Pathway for Biosimilars Act H.R.1706/S.369 - Protecting Consumer Access to Generic Drugs Act of 2009 / Preserve Access to Affordable Generics Act of 2009 H.R.3200/S.1796- America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act H.R.3962 - Affordable Health Care for America Act H.R.4872 - Health Care and Education Reconciliation Act of 2010 H.R.4956 - Stop Oxy Abuse Act of 2010 H.R.756/S.660 - National Pain Care Policy Act of 2009 H.R.5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165/S.4018 -Life Sciences Jobs and Investment Act of 2010 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $270,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S.27 - Preserve Access to Affordable Generics Act S.301 - Physician Payments Sunshine Act of 2009 S.319 - Pharmaceutical Market Access and Drug Safety Act of 2011 H.R.1191/S.1336 - Safe Drug Disposal Act of 2009 H.R.1260/S.515 & 610 - Patent Reform Act of 2009 H.R.1298/S.525 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 - Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 - Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 - Pathway for Biosimilars Act H.R.1706/S.369 - Protecting Consumer Access to Generic Drugs Act of 2009 / Preserve Access to Affordable Generics Act of 2009 H.R.3200/S.1796- America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act H.R.3962 - Affordable Health Care for America Act H.R.4872 - Health Care and Education Reconciliation Act of 2010 H.R.4956 - Stop Oxy Abuse Act of 2010 H.R.756/S.660 - National Pain Care Policy Act of 2009 H.R.5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165/S.4018 -Life Sciences Jobs and Investment Act of 2010 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $270,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S.27 - Preserve Access to Affordable Generics Act S.301 - Physician Payments Sunshine Act of 2009 S.319 - Pharmaceutical Market Access and Drug Safety Act of 2011 H.R.1191/S.1336 - Safe Drug Disposal Act of 2009 H.R.1260/S.515 & 610 - Patent Reform Act of 2009 H.R.1298/S.525 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 - Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 - Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 - Pathway for Biosimilars Act H.R.1706/S.369 - Protecting Consumer Access to Generic Drugs Act of 2009 / Preserve Access to Affordable Generics Act of 2009 H.R.3200/S.1796- America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act H.R.3962 - Affordable Health Care for America Act H.R.4872 - Health Care and Education Reconciliation Act of 2010 H.R.4956 - Stop Oxy Abuse Act of 2010 H.R.756/S.660 - National Pain Care Policy Act of 2009 H.R.5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165/S.4018 -Life Sciences Jobs and Investment Act of 2010 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $270,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 3590 Patient Protection and Affordable Care Act, Pub. Law No: 111-148 (PPACA); H.R. 451, Healthcare Truth and Transparency Act: Healthcare Provider Transparency, Healthcare Provider Misrepresentation National All Schedules Prescription Electronic Reporting Reauthorization Act H.R. 4872, The Health Care and Education Affordability Reconciliation Act of 2010 H.R. 5808, To amend the Patient Protection and Affordable Care Act to establish a public health insurance option PPACA Nondiscrimination language regarding paraprofessionals H.R. 756, National Pain Care Policy Act, S.660, National Pain Care Policy Act DEA Scheduling Propofol Comparative Effectiveness Research Hospital Acquired Infections HITECH Implemenation, Electronic Health Records, Final and Proposed Rules, HIT Meaningful Use HHS/OIG Anesthesia Practice Arrangements, Company Model FDA Risk Evaluation and Mitigation Strategies Physician Antitrust Relief Physician Workforce Issues Medical Liability Reform; H.R. 5, HEALTH Act of 2011 FDA Safe Use Initiative S. 296, Preserving Access to Life-saving Medications Act, drug shortages Pain Management Pediatric Anesthesia FDA Operating Room Fires FDA ACTION Initiative FDA Propofol Shortage FDA Sentinel Prescription Drug User Fee Act Deep sedation NASPER Funding; controlled substance abuse, misuse and diversion Required Physician Supervision of Nurse Anesthetists, Nurse error rates State Exchanges pursuant to PPACA Patient Safety Initiatives FDA SEDASYS FDA Sedation Products Request for Assistance

Client expense: $210,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), SENATE

S.301 - Physician Payments Sunshine Act of 2009 H.R.1191/S.1336 - Safe Drug Disposal Act of 2009 H.R.1260/S.515 & 610 - Patent Reform Act of 2009 H.R.1298/S.525 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 - Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 - Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 - Pathway for Biosimilars Act H.R.1706/S.369 - Protecting Consumer Access to Generic Drugs Act of 2009 / Preserve Access to Affordable Generics Act of 2009 H.R.3200/S.1796- America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act H.R.3962 - Affordable Health Care for America Act H.R.4872 - Health Care and Education Reconciliation Act of 2010 H.R.4956 - Stop Oxy Abuse Act of 2010 H.R.756/S.660 - National Pain Care Policy Act of 2009 H.R.5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165/S.4018 -Life Sciences Jobs and Investment Act of 2010 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S.301 - Physician Payments Sunshine Act of 2009 H.R.1191/S.1336 - Safe Drug Disposal Act of 2009 H.R.1260/S.515 & 610 - Patent Reform Act of 2009 H.R.1298/S.525 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 - Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 - Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 - Pathway for Biosimilars Act H.R.1706/S.369 - Protecting Consumer Access to Generic Drugs Act of 2009 / Preserve Access to Affordable Generics Act of 2009 H.R.3200/S.1796- America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act H.R.3962 - Affordable Health Care for America Act H.R.4872 - Health Care and Education Reconciliation Act of 2010 H.R.4956 - Stop Oxy Abuse Act of 2010 H.R.756/S.660 - National Pain Care Policy Act of 2009 H.R.5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165/S.4018 -Life Sciences Jobs and Investment Act of 2010 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S.301 - Physician Payments Sunshine Act of 2009 H.R.1191/S.1336 - Safe Drug Disposal Act of 2009 H.R.1260/S.515 & 610 - Patent Reform Act of 2009 H.R.1298/S.525 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 - Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 - Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 - Pathway for Biosimilars Act H.R.1706/S.369 - Protecting Consumer Access to Generic Drugs Act of 2009 / Preserve Access to Affordable Generics Act of 2009 H.R.3200/S.1796- America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act H.R.3962 - Affordable Health Care for America Act H.R.4872 - Health Care and Education Reconciliation Act of 2010 H.R.4956 - Stop Oxy Abuse Act of 2010 H.R.756/S.660 - National Pain Care Policy Act of 2009 H.R.5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165/S.4018 -Life Sciences Jobs and Investment Act of 2010 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S.301 - Physician Payments Sunshine Act of 2009 H.R.1191/S.1336 - Safe Drug Disposal Act of 2009 H.R.1260/S.515 & 610 - Patent Reform Act of 2009 H.R.1298/S.525 - Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 - Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 - Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 - Pathway for Biosimilars Act H.R.1706/S.369 - Protecting Consumer Access to Generic Drugs Act of 2009 / Preserve Access to Affordable Generics Act of 2009 H.R.3200/S.1796- America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009 H.R.3590 - Patient Protection and Affordable Care Act H.R.3962 - Affordable Health Care for America Act H.R.4872 - Health Care and Education Reconciliation Act of 2010 H.R.4956 - Stop Oxy Abuse Act of 2010 H.R.756/S.660 - National Pain Care Policy Act of 2009 H.R.5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165/S.4018 -Life Sciences Jobs and Investment Act of 2010 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans. Support Efforts to Eliminate "Lifetime Caps" on health insurance benefits. Support Part D Medicare Coverage Gap Discount Program "draft guidance" to improve the program for beneficiaries. Oppose Recess Appointment of Dr. Donald Berwick as CMS Administrator. Support expanded screening for Osteoporosis for both women and men under new coverage rules. Support nomination of Peter Pitts for the Patient-Centered Outcomes Research Institute Board of Governors. Support Medicare reimbursement for Provenge to treat prostate cancer. Support the most stringent and rigorous testing of biosimilars that would or could be used as replacements for the original, innovator biologic drugs. Support the Council for American Medical Innovation comments to The National Commission on Fiscal Responsibility and Reform regarding the continuing need for spending to promote medical innovation to save lives and money. Support the Partnership to Fight Chronic Disease response to the Agency for Healthcare Research and Quality request for feedback on the National Quality Strategy and Plan development in regards to the Affordable Care Act.

Client expense: $76,368 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office

S. 488/H.R. 716 - Access to Cancer Clinical Trials Act of 2009; H.R. 1189 - Colorectal Cancer Prevention, Early Detection, and Treatment Act of 2009; H.R. 1330 - Colorectal Cancer Screening and Detection Coverage Act of 2009; H.R. 756/S. 660 - National Pain Policy Act of 2009; S. 497/H.R. 2043 - Nurse Education, Expansion, and Development Act of 2009; Health Reform; Health Workforce Shortage Issues; S. 623/H.R. 1558 - Preexisting Condition Exclusion Patient Protection Act of 2009; (Continued) S. 643/H.R. 1619 - Children's Health Protection Act of 2009; S. 688/H.R. 1691 - Breast Cancer Patient Protection Act; H.R. 2366 - Cancer Drug Coverage Parity Act; FDA Regulation of Opioids; H.R. 2115- Men and Familes Health Care Act; Health Care Reform; H.R. 3962 - Affordable Health Care for America Act; H.R. 3590 - Patient Protection and Affordable Care Act; H.R. 4872 - Reconciliation Act of 2010.

Client expense: Not reported · Firm income: $40,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, White House Office

S. 488/H.R. 716 - Access to Cancer Clinical Trials Act of 2009; H.R. 1189 - Colorectal Cancer Prevention, Early Detection, and Treatment Act of 2009; H.R. 1330 - Colorectal Cancer Screening and Detection Coverage Act of 2009; H.R. 756/S. 660 - National Pain Policy Act of 2009; S. 497/H.R. 2043 - Nurse Education, Expansion, and Development Act of 2009; Health Reform; Health Workforce Shortage Issues; S. 623/H.R. 1558 - Preexisting Condition Exclusion Patient Protection Act of 2009; (Continued) S. 643/H.R. 1619 - Children's Health Protection Act of 2009; S. 688/H.R. 1691 - Breast Cancer Patient Protection Act; H.R. 2366 - Cancer Drug Coverage Parity Act; FDA Regulation of Opioids; H.R. 2115- Men and Familes Health Care Act; Health Care Reform; H.R. 3962 - Affordable Health Care for America Act; H.R. 3590 - Patient Protection and Affordable Care Act; H.R. 4872 - Reconciliation Act of 2010.

Client expense: Not reported · Firm income: $40,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, White House Office

H.R.914, Physician Workforce Enhancement Act of 2009, Addiction treatment workforce development. S.790, Health Access and Health Professions Supply Act of 2009, Addiction treatment workforce development. Add to #17 below: National Institute of Drug Abuse (NIDA); and Center for Substance Abuse Treatment (CSAT) H.R.756/S.660, National Pain Care Policy Act of 2009, Pain care related issues. Public Law 111-148, Patient Protection and Affordable Care Act, Addiction treatment issues. Public Law 111-152, Health Care and Education Reconciliation Act of 2010, Addiction treatment issues. H.R.5392, Council on Integration of Health Care Education Act of 2010, Addiction Medicine Education issues.

Client expense: Not reported · Firm income: $40,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

H.R. 3590 Patient Protection and Affordable Care Act, Pub. Law No: 111-148 H.R. 5710, National All Schedules Prescription Electronic Reporting Reauthorization Act H.R. 4872, The Health Care and Education Affordability Reconciliation Act of 2010 H.R. 5808, To amend the Patient Protection and Affordable Care Act to establish a public health insurance option. Nondiscrimination language regarding paraprofessionals H.R. 5295, Healthcare Truth and Transparency Act: Healthcare Provider Transparency, Healthcare Provider Misrepresentation H.R. 756, National Pain Care Policy Act, S.660, National Pain Care Policy Act DEA E-Prescribing DEA Propofol Comparative Effectiveness Research Hospital Acquired Infections HITECH Implemenation, Electronic Health Records, Final and Proposed Rules, HIT Meaningful Use Data Registry Funding HHS/OIG Anesthesia Practice Arrangements, Company Model FDA Risk Evaluation and Mitigation Strategies Physician Antitrust Relief Physician Workforce Issues Medical Liability Reform FDA Safe Use Initiative FDA Operating Room Fires FDA ACTION Initiative FDA Propofol Shortage FDA Scheduling of Propofol FDA Sentinel Non-Anesthesia Provider Use of Propofol Prescription Drug User Fee Act Deep sedation NASPER Funding; controlled substance abuse, misuse and diversion Required Physician Supervision of Nurse Anesthetists, Nurse error rates State Exchanges pursuant to PPACA Patient Safety Initiatives FDA SEDASYS FDA Sedation Products Request for Assistance Interventional Pain OSHA Resident Hours regulation

Client expense: $210,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Occupational Safety & Health Administration (OSHA), Office of Management & Budget (OMB), SENATE

H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans. Support Efforts to Eliminate "Lifetime Caps" on health insurance benefits. Support Part D Medicare Coverage Gap Discount Program "draft guidance" to improve the program for beneficiaries. Oppose Recess Appointment of Dr. Donald Berwick as CMS Administrator. Support expanded screening for Osteoporosis for both women and men under new coverage rules. Support nomination of Peter Pitts for the Patient-Centered Outcomes Research Institute Board of Governors. Support Medicare reimbursement for Provenge to treat prostate cancer. Support the most stringent and rigorous testing of biosimilars that would or could be used as replacements for the original, innovator biologic drugs. Support the Council for American Medical Innovation comments to The National Commission on Fiscal Responsibility and Reform regarding the continuing need for spending to promote medical innovation to save lives and money. Support the Partnership to Fight Chronic Disease response to the Agency for Healthcare Research and Quality request for feedback on the National Quality Strategy and Plan development in regards to the Affordable Care Act.

Client expense: Not reported · Firm income: $13,310

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office

Implementation of H.R. 3590, the Patient Protection and Affordable Care Act, to provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. Implementation of H.R. 4872, the Health Care and Reconciliation Act of 2010, a bill that makes a number of health-related financing and revenue changes to the Patient Protection and Affordable Care Act, specifically regarding the medical device tax. S.540, Medical Device Safety Act, a bill that would remove federal preemption protection for certain medical devices H.R.1346, Medical Device Safety Act, a bill that would remove federal preemption protection for certain medical devices Reform of the 510 (k) regulatory pathway H.R. 759, Food and Drug Administration Globalization Act, a bill to improve the safety of food, drugs, devices, and cosmetics S. 882, the Drug and Device Accountability Act, a bill to ensure the safety and quality of medical products and enhance the authorities of the FDA H.R. 2502, Comparative Effectiveness Research Act of 2009, a bill to provide for the conduct of comparative effectiveness research for drugs, devices, and other therapies and create a Comparative Effectiveness Research Trust Fund S.1213, Patient-Centered Outcomes Research Act of 2009, a bill to provide for the conduct of comparative effectiveness research for drugs, devices, and other therapies and to establish a Patient-Centered Outcomes Research Trust Fund H.R. 2824, Doctor-Patient Relationship and Research Protection Act, a bill to support federally funded comparative effectiveness research for drugs, devices, and other therapies S.1142, Informed Health Care Decision Making Act, a bill with respect to the inclusion of effectiveness information in drug and device labeling and advertising H.R. 3090, Health Equity & Accountability Act of 2009, provides for the elimination of racial and ethnic health disparities S.660, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies H.R. 756, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies H.R. 4700, the Transparency in All Health Care Pricing Act of 2010, to provide for transparency in health care pricing H.R. 2249, the Health Care Price Transparency Promotion Act of 2009, to provide for increased price transparency of hospital information and to provide for additional research on consumer information on charges and out-of-pocket costs. H.R. 4803, the Patients Right to Know Act, to ensure health care consumer and provider access to certain health benefits plan information and to amend title XIX of the Social Security Act to provide transparency in hospital price and quality information. H.R.1032, Heart Disease Education, Analysis Research, and Treatment for Women Act to amend the Public Health Service Act to improve the prevention, diagnosis, and treatment of heart disease, stroke, and other cardiovascular diseases in women. S.422, Heart Disease Education, Analysis Research, and Treatment for Women Act to amend the Public Health Service Act to improve the prevention, diagnosis, and treatment of heart disease, stroke, and other cardiovascular diseases in women.

Client expense: $450,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Transportation, Dept of (DOT)

S.660, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies H.R. 756, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies S.1380, Medicare Payment Advisory Commission (MedPAC) Reform Act, a bill to make the commission an executive branch agency, and provide the Commission new resources and authority to implement Medicare payment policy S.301, Physician Payments Sunshine Act, a bill that would require disclosure of the relationships between physicians and the manufacturers of drugs and devices H.R. 3138, Physician Payments Sunshine Act, a bill that would require disclosure of the relationships between physicians and the manufacturers of drugs and devices H.R. 2502, Comparative Effectiveness Research Act of 2009, a bill to provide for the conduct of comparative effectiveness research for drugs, devices, and other therapies and create a Comparative Effectiveness Research Trust Fund S.1213, Patient-Centered Outcomes Research Act of 2009, a bill to provide for the conduct of comparative effectiveness research for drugs, devices, and other therapies and to establish a Patient-Centered Outcomes Research Trust Fund H.R. 2824, Doctor-Patient Relationship and Research Protection Act, a bill to support federally funded comparative effectiveness research for drugs, devices, and other therapies S.1142, Informed Health Care Decision Making Act, a bill with respect to the inclusion of effectiveness information in drug and device labeling and advertising H.R. 4700, the Transparency in All Health Care Pricing Act of 2010, to provide for transparency in health care pricing H.R. 2249, the Health Care Price Transparency Promotion Act of 2009, to provide for increased price transparency of hospital information and to provide for additional research on consumer information on charges and out-of-pocket costs. H.R. 4803, the Patients Right to Know Act, to ensure health care consumer and provider access to certain health benefits plan information and to amend title XIX of the Social Security Act to provide transparency in hospital price and quality information

Client expense: $450,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Transportation, Dept of (DOT)

H.R.756 and S.660; National Pain Care Policy Act of 2009; Health Care Reform; H.R.3200/S.1679; H.R.3962; H.R.3590; FDA Opioid REMS Policy and Telemedicine; amd Medicare Fraud & Abuse.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.914, Physician Workforce Enhancement Act of 2009, Addiction treatment workforce development. S.790, Health Access and Health Professions Supply Act of 2009, Addiction treatment workforce development. Add to #17 below: National Institute of Drug Abuse (NIDA); and Center for Substance Abuse Treatment (CSAT) H.R.756/S.660, National Pain Care Policy Act of 2009, Pain care related issues. Public Law 111-148, Patient Protection and Affordable Care Act, Addiction treatment issues. Public Law 111-152, Health Care and Education Reconciliation Act of 2010, Addiction treatment issues. H.R.5392, Council on Integration of Health Care Education Act of 2010, Addiction Medicine Education issues.

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans. Support Efforts to Eliminate "Lifetime Caps" on health insurance benefits. Support Part D Medicare Coverage Gap Discount Program "draft guidance" to improve the program for beneficiaries. Oppose Recess Appointment of Dr. Donald Berwick as CMS Administrator. Support expanded screening for Osteoporosis for both women and men under new coverage rules. Support nomination of Peter Pitts for the Patient-Centered Outcomes Research Institute Board of Governors.

Client expense: $176,190 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office

H.R.756 and S.660; National Pain Care Policy Act of 2009; Health Care Reform; H.R.3200/S.1679; H.R.3962; H.R.3590; FDA Opioid REMS Policy and Telemedicine.

Client expense: Not reported · Firm income: $50,000

Government targets: Federal Communications Commission (FCC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS)

S. 488/H.R. 716 - Access to Cancer Clinical Trials Act of 2009; H.R. 1189 - Colorectal Cancer Prevention, Early Detection, and Treatment Act of 2009; H.R. 1330 - Colorectal Cancer Screening and Detection Coverage Act of 2009; H.R. 756/S. 660 - National Pain Policy Act of 2009; S. 497/H.R. 2043 - Nurse Education, Expansion, and Development Act of 2009; Health Reform; Health Workforce Shortage Issues; S. 623/H.R. 1558 - Preexisting Condition Exclusion Patient Protection Act of 2009; (Continued) S. 643/H.R. 1619 - Children's Health Protection Act of 2009; S. 688/H.R. 1691 - Breast Cancer Patient Protection Act; H.R. 2366 - Cancer Drug Coverage Parity Act; FDA Regulation of Opioids; H.R. 2115- Men and Familes Health Care Act; Health Care Reform; H.R. 3962 - Affordable Health Care for America Act; H.R. 3590 - Patient Protection and Affordable Care Act; H.R. 4872 - Reconciliation Act of 2010.

Client expense: Not reported · Firm income: $40,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, White House Office

Implementation of H.R. 3590, the Patient Protection and Affordable Care Act, to provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. Implementation of H.R. 4872, the Health Care and Reconciliation Act of 2010, a bill that makes a number of health-related financing and revenue changes to the Patient Protection and Affordable Care Act, specifically regarding the medical device tax. S.540, Medical Device Safety Act, a bill that would remove federal preemption protection for certain medical devices H.R.1346, Medical Device Safety Act, a bill that would remove federal preemption protection for certain medical devices Reform of the 510 (k) regulatory pathway H.R. 759, Food and Drug Administration Globalization Act, a bill to improve the safety of food, drugs, devices, and cosmetics S. 882, the Drug and Device Accountability Act, a bill to ensure the safety and quality of medical products and enhance the authorities of the FDA H.R. 2502, Comparative Effectiveness Research Act of 2009, a bill to provide for the conduct of comparative effectiveness research for drugs, devices, and other therapies and create a Comparative Effectiveness Research Trust Fund S.1213, Patient-Centered Outcomes Research Act of 2009, a bill to provide for the conduct of comparative effectiveness research for drugs, devices, and other therapies and to establish a Patient-Centered Outcomes Research Trust Fund H.R. 2824, Doctor-Patient Relationship and Research Protection Act, a bill to support federally funded comparative effectiveness research for drugs, devices, and other therapies S.1142, Informed Health Care Decision Making Act, a bill with respect to the inclusion of effectiveness information in drug and device labeling and advertising H.R. 3090, Health Equity & Accountability Act of 2009, provides for the elimination of racial and ethnic health disparities S.660, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies H.R. 756, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies H.R. 4700, the Transparency in All Health Care Pricing Act of 2010, to provide for transparency in health care pricing H.R. 2249, the Health Care Price Transparency Promotion Act of 2009, to provide for increased price transparency of hospital information and to provide for additional research on consumer information on charges and out-of-pocket costs. H.R. 4803, the Patients Right to Know Act, to ensure health care consumer and provider access to certain health benefits plan information and to amend title XIX of the Social Security Act to provide transparency in hospital price and quality information. H.R.1032, Heart Disease Education, Analysis Research, and Treatment for Women Act to amend the Public Health Service Act to improve the prevention, diagnosis, and treatment of heart disease, stroke, and other cardiovascular diseases in women. S.422, Heart Disease Education, Analysis Research, and Treatment for Women Act to amend the Public Health Service Act to improve the prevention, diagnosis, and treatment of heart disease, stroke, and other cardiovascular diseases in women.

Client expense: $490,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Transportation, Dept of (DOT)

S.660, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies H.R. 756, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies S.1380, Medicare Payment Advisory Commission (MedPAC) Reform Act, a bill to make the commission an executive branch agency, and provide the Commission new resources and authority to implement Medicare payment policy S.301, Physician Payments Sunshine Act, a bill that would require disclosure of the relationships between physicians and the manufacturers of drugs and devices H.R. 3138, Physician Payments Sunshine Act, a bill that would require disclosure of the relationships between physicians and the manufacturers of drugs and devices H.R. 2502, Comparative Effectiveness Research Act of 2009, a bill to provide for the conduct of comparative effectiveness research for drugs, devices, and other therapies and create a Comparative Effectiveness Research Trust Fund S.1213, Patient-Centered Outcomes Research Act of 2009, a bill to provide for the conduct of comparative effectiveness research for drugs, devices, and other therapies and to establish a Patient-Centered Outcomes Research Trust Fund H.R. 2824, Doctor-Patient Relationship and Research Protection Act, a bill to support federally funded comparative effectiveness research for drugs, devices, and other therapies S.1142, Informed Health Care Decision Making Act, a bill with respect to the inclusion of effectiveness information in drug and device labeling and advertising H.R. 4700, the Transparency in All Health Care Pricing Act of 2010, to provide for transparency in health care pricing H.R. 2249, the Health Care Price Transparency Promotion Act of 2009, to provide for increased price transparency of hospital information and to provide for additional research on consumer information on charges and out-of-pocket costs. H.R. 4803, the Patients Right to Know Act, to ensure health care consumer and provider access to certain health benefits plan information and to amend title XIX of the Social Security Act to provide transparency in hospital price and quality information

Client expense: $490,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Transportation, Dept of (DOT)

H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans. Support Efforts to Eliminate "Lifetime Caps" on health insurance benefits. Support Part D Medicare Coverage Gap Discount Program "draft guidance" to improve the program for beneficiaries. Oppose Recess Appointment of Dr. Donald Berwick as CMS Administrator. Support expanded screening for Osteoporosis for both women and men under new coverage rules. Support nomination of Peter Pitts for the Patient-Centered Outcomes Research Institute Board of Governors.

Client expense: Not reported · Firm income: $13,695

Government targets: Centers For Medicare and Medicaid Services (CMS), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office

H.R.756/S.660 National Pain Care Policy Act of 2009 H.R.1191/S. 1336 Safe Drug Disposal Act of 2009 H.R.1260/S.515/S.610 Patent Reform Act of 2009 H.R.1298/S.525 Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 Pathway for Biosimilars Act H.R.1706 Protecting Consumer Access to Generic Drugs Act of 2009 H.R.3200 America's Affordable Health Choices Act of 2009 H.R.3590 Patient Protection and Affordable Care Act H.R.3962 Affordable Health Care for America Act H.R.4872 Health Care and Education Reconciliation Act of 2010 H.R.4956 Stop Oxy Abuse Act of 2010 H.R.5712 VeteranS', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165 Life Sciences Jobs and Investment Act of 2010 S.301 Physician Payments Sunshine Act of 2009 S.369 Preserve Access to Affordable Generics Act of 2009 S.1796 America's Healthy Future Act of 2009 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $240,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R.756/S.660 National Pain Care Policy Act of 2009 H.R.1191/S. 1336 Safe Drug Disposal Act of 2009 H.R.1260/S.515/S.610 Patent Reform Act of 2009 H.R.1298/S.525 Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 Pathway for Biosimilars Act H.R.1706 Protecting Consumer Access to Generic Drugs Act of 2009 H.R.3200 America's Affordable Health Choices Act of 2009 H.R.3590 Patient Protection and Affordable Care Act H.R.3962 Affordable Health Care for America Act H.R.4872 Health Care and Education Reconciliation Act of 2010 H.R.4956 Stop Oxy Abuse Act of 2010 H.R.5712 VeteranS', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165 Life Sciences Jobs and Investment Act of 2010 S.301 Physician Payments Sunshine Act of 2009 S.369 Preserve Access to Affordable Generics Act of 2009 S.1796 America's Healthy Future Act of 2009 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $240,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R.756/S.660 National Pain Care Policy Act of 2009 H.R.1191/S. 1336 Safe Drug Disposal Act of 2009 H.R.1260/S.515/S.610 Patent Reform Act of 2009 H.R.1298/S.525 Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 Pathway for Biosimilars Act H.R.1706 Protecting Consumer Access to Generic Drugs Act of 2009 H.R.3200 America's Affordable Health Choices Act of 2009 H.R.3590 Patient Protection and Affordable Care Act H.R.3962 Affordable Health Care for America Act H.R.4872 Health Care and Education Reconciliation Act of 2010 H.R.4956 Stop Oxy Abuse Act of 2010 H.R.5712 VeteranS', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165 Life Sciences Jobs and Investment Act of 2010 S.301 Physician Payments Sunshine Act of 2009 S.369 Preserve Access to Affordable Generics Act of 2009 S.1796 America's Healthy Future Act of 2009 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $240,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R.756/S.660 National Pain Care Policy Act of 2009 H.R.1191/S. 1336 Safe Drug Disposal Act of 2009 H.R.1260/S.515/S.610 Patent Reform Act of 2009 H.R.1298/S.525 Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 Pathway for Biosimilars Act H.R.1706 Protecting Consumer Access to Generic Drugs Act of 2009 H.R.3200 America's Affordable Health Choices Act of 2009 H.R.3590 Patient Protection and Affordable Care Act H.R.3962 Affordable Health Care for America Act H.R.4872 Health Care and Education Reconciliation Act of 2010 H.R.4956 Stop Oxy Abuse Act of 2010 H.R.5712 VeteranS', Seniors', and Children's Health Technical Corrections Act of 2010 H.R.5809/S.3397Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010 H.R.6165 Life Sciences Jobs and Investment Act of 2010 S.301 Physician Payments Sunshine Act of 2009 S.369 Preserve Access to Affordable Generics Act of 2009 S.1796 America's Healthy Future Act of 2009 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $240,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Healthcare Reform: S.391, H.R. 1321 Healthy Americans Act; H.R. 193 American Healthcare Act; H.R. 3200, America's Affordable Health Choices Act; America's Healthy Futures Act of 2009; H.R. 3962, Affordable Healthcare for America Act; H.R. 3590 Patient Protection and Affordable Care Act, Pub. Law No: 111-148 H.R. 5710, National All Schedules Prescription Electronic Reporting Reauthorization Act H.R. 4872, The Health Care and Education Affordability Reconciliation Act of 2010 H.R. 5808, To amend the Patient Protection and Affordable Care Act to establish a public health insurance option. Nondiscrimination language regarding paraprofessionals H.R. 5295, Healthcare Truth and Transparency Act: Healthcare Provider Transparency, Healthcare Provider Misrepresentation H.R. 756, National Pain Care Policy Act, S.660, National Pain Care Policy Act DEA E-Prescribing DEA Propofol Comparative Effectiveness Research Hospital Acquired Infections HITECH Implemenation, Electronic Health Records, Final and Proposed Rules, HIT Meaningful Use Data Registry Funding HHS/OIG Anesthesia Practice Arrangements, Company Model FDA Risk Evaluation and Mitigation Strategies Physician Antitrust Relief Physician Workforce Issues Medical Liability Reform FDA Safe Use Initiative FDA Operating Room Fires FDA ACTION Initiative FDA Propofol Shortage Compliance with Senate Finance Committee request FDA Scheduling of Propofol FDA Sentinel Non-Anesthesia Provider Use of Propofol Prescription Drug User Fee Act Deep sedation NASPER Funding Required Physician Supervision of Nurse Anesthetists, Nurse error rates State Exchanges pursuant to PPACA Patient Safety Initiatives

Client expense: $210,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE

H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans. Support Efforts to Eliminate "Lifetime Caps" on health insurance benefits. Support Part D Medicare Coverage Gap Discount Program "draft guidance" to improve the program for beneficiaries. Oppose Recess Appointment of Dr. Donald Berwick as CMS Administrator.

Client expense: $172,523 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office

H.R.756/S.660 National Pain Care Policy Act of 2009 H.R.1191/S. 1336 Safe Drug Disposal Act of 2009 H.R.1260/S.515/S.610 Patent Reform Act of 2009 H.R.1298/S.525 Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 Pathway for Biosimilars Act H.R.1706 Protecting Consumer Access to Generic Drugs Act of 2009 H.R.3200 America's Affordable Health Choices Act of 2009 H.R.3590 Patient Protection and Affordable Care Act H.R.3962 Affordable Health Care for America Act H.R.4872 Health Care and Education Reconciliation Act of 2010 H.R.4956 Stop Oxy Abuse Act of 2010 H.R.5712 VeteranS', Seniors', and Children's Health Technical Corrections Act of 2010 S.301 Physician Payments Sunshine Act of 2009 S.369 Preserve Access to Affordable Generics Act of 2009 S.1796 America's Healthy Future Act of 2009 SPECIFIC ISSUES Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $276,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R.756/S.660 National Pain Care Policy Act of 2009 H.R.1191/S. 1336 Safe Drug Disposal Act of 2009 H.R.1260/S.515/S.610 Patent Reform Act of 2009 H.R.1298/S.525 Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 Pathway for Biosimilars Act H.R.1706 Protecting Consumer Access to Generic Drugs Act of 2009 H.R.3200 America's Affordable Health Choices Act of 2009 H.R.3590 Patient Protection and Affordable Care Act H.R.3962 Affordable Health Care for America Act H.R.4872 Health Care and Education Reconciliation Act of 2010 H.R.4956 Stop Oxy Abuse Act of 2010 H.R.5712 VeteranS', Seniors', and Children's Health Technical Corrections Act of 2010 S.301 Physician Payments Sunshine Act of 2009 S.369 Preserve Access to Affordable Generics Act of 2009 S.1796 America's Healthy Future Act of 2009 SPECIFIC ISSUES Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $276,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R.756/S.660 National Pain Care Policy Act of 2009 H.R.1191/S. 1336 Safe Drug Disposal Act of 2009 H.R.1260/S.515/S.610 Patent Reform Act of 2009 H.R.1298/S.525 Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 Pathway for Biosimilars Act H.R.1706 Protecting Consumer Access to Generic Drugs Act of 2009 H.R.3200 America's Affordable Health Choices Act of 2009 H.R.3590 Patient Protection and Affordable Care Act H.R.3962 Affordable Health Care for America Act H.R.4872 Health Care and Education Reconciliation Act of 2010 H.R.4956 Stop Oxy Abuse Act of 2010 H.R.5712 VeteranS', Seniors', and Children's Health Technical Corrections Act of 2010 S.301 Physician Payments Sunshine Act of 2009 S.369 Preserve Access to Affordable Generics Act of 2009 S.1796 America's Healthy Future Act of 2009 Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $276,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R.756/S.660 National Pain Care Policy Act of 2009 H.R.1191/S. 1336 Safe Drug Disposal Act of 2009 H.R.1260/S.515/S.610 Patent Reform Act of 2009 H.R.1298/S.525 Pharmaceutical Market Access and Drug Safety Act of 2009 H.R.1359/S.1292 Secure and Responsible Drug Disposal Act of 2009 H.R.1427/S.726 Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548 Pathway for Biosimilars Act H.R.1706 Protecting Consumer Access to Generic Drugs Act of 2009 H.R.3200 America's Affordable Health Choices Act of 2009 H.R.3590 Patient Protection and Affordable Care Act H.R.3962 Affordable Health Care for America Act H.R.4872 Health Care and Education Reconciliation Act of 2010 H.R.4956 Stop Oxy Abuse Act of 2010 H.R.5712 VeteranS', Seniors', and Children's Health Technical Corrections Act of 2010 S.301 Physician Payments Sunshine Act of 2009 S.369 Preserve Access to Affordable Generics Act of 2009 S.1796 America's Healthy Future Act of 2009 SPECIFIC ISSUES Anti- counterfeiting legislation concerning drugs (pedigree) Biosimilar Drugs Disposal of Drugs Drug Reimportation Healthcare Reform Hearings related to prescription drug abuse and prevention Life sciences research tax credit legislation Patent Settlements Pedigree Legislation Prescription Drug User Fee Act reauthorization RiskEvaluation and MitigationStrategies for controlled substances Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)

Client expense: $276,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR 3151/S 1585 Rural Access to Nurse Anesthesia Services Act of 2009; HR 756/S 660 National Pain Care Policy Act of 2009

Client expense: $749,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE

Healthcare Reform: S.391, H.R. 1321 Healthy Americans Act; H.R. 193 American Healthcare Act; H.R. 3200, America's Affordable Health Choices Act; America's Healthy Futures Act of 2009; H.R. 3962, Affordable Healthcare for America Act; H.R. 3590 Patient Protection and Affordable Care Act, Pub. Law No: 111-148 H.R. 4872, The Health Care and Education Affordability Reconciliation Act of 2010 Nondiscrimination language regarding paraprofessionals Independent Payment Advisory Board (IPAB) Anesthesia Conversion factor H.R. 5295, Healthcare Truth and Transparency Act: Healthcare Provider Transparency, Healthcare Provider Misrepresentation H.R. 756, National Pain Care Policy Act, S.660, National Pain Care Policy Act FDA Ethicon Endo-Surgery SEDASYS System DEA E-Prescribing DEA Propofol Comparative Effectiveness Research Hospital Acquired Infections American Recovery and Reinvestment Act of 2009: Health Information Technology, Stimulus Bill, HITECH Data Registry Funding HHS/OIG Anesthesia Practice Arrangements FDA Risk Evaluation and Mitigation Strategies Physician Antitrust Relief Physician Workforce Issues Medical Liability Reform FDA Safe Use Initiative HIT Meaningful Use FDA Operating Room Fires FDA ACTION Initiative FDA Propofol Shortage Public Plan - Negotiated Provider payment rates OIG Company Model issue Compliance with Senate Finance Committee request FDA Scheduling of Propofol FDA Sentinel Non-Anesthesia Provider Use of Propofol Prescription Drug User Fee Act Deep sedation

Client expense: $340,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE

H.R.914, Physician Workforce Enhancement Act of 2009, Addiction treatment workforce development. S.790, Health Access and Health Professions Supply Act of 2009, Addiction treatment workforce development. Add to #17 below: National Institute of Drug Abuse (NIDA); and Center for Substance Abuse Treatment (CSAT) H.R.756/S.660, National Pain Care Policy Act of 2009, Pain care related issues. Public Law 111-148, Patient Protection and Affordable Care Act, Addiction treatment issues. Public Law 111-152, Health Care and Education Reconciliation Act of 2010, Addiction treatment issues. H.R.5392, Council on Integration of Health Care Education Act of 2010, Addiction Medicine Education issues.

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Lobbying on scope of Physician Payments Sunshine Act (S. 301); general Medicare and Medicade reform issues (America's Affordable Health Choices Act of 2009 H.R. 3200, Affordable Health Choices Act S. 1679); electronic prescribing issues (no specific legislation); anti-counterfeiting legislation concerning drugs/pedigree drug legislation; legislation on drug and device safety (Food and Drug Administration Globalization Act of 2009 H.R. 759); generic drug legislation (H.R. 573); follow-on biologics (Pre-existing Condition Patient Protection Act of 2009 S. 623); Medicare Prescription Drug Savings and Choice Act of 2009 (S. 330 & H.R. 684); drug disposal legislation (Secure and Responsible Drug Disposal Act of 2009 H.R. 1359 and Safe Drug Disposal Act of 2009 H.R. 1191, S. 1292, S. 1336); federal preemption issues in Medical Device Safety Act of 2009 (S. 540 and H.R. 1346); National Pain Care Policy Act of 2009 (H.R. 756 & S. 660); drug reimportation issues (Pharmaceutical Market Access and Drug Safety Act of 2009, S. 525 & H.R. 1298); disposal of drugs (H.R. 1191, H.R. 1359, S. 1292 & S. 1336); biosimilar drugs (H.R. 1427, H.R. 1548, S. 726); tax on pharmaceutical companies (H.R. 3590, S. 1796); health care reform (America's Affordable Health Choices Act of 2009 H.R. 3200, Affordable Health Choices Act S. 1679, America's Healthy Future Act S. 1796, H.R. 3590, H.R. 3962, H.R. 3200, H.R. 4872); modify approval of oxycodone (H.R. 4956); reauthorization of Prescription Drug User Fee Act; health care technical corrections (H.R. 5712); life sciences research tax credit legislation.

Client expense: $360,000 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE

S. 488/H.R. 716 - Access to Cancer Clinical Trials Act of 2009; H.R. 1189 - Colorectal Cancer Prevention, Early Detection, and Treatment Act of 2009; H.R. 1330 - Colorectal Cancer Screening and Detection Coverage Act of 2009; H.R. 756/S. 660 - National Pain Policy Act of 2009; S. 497/H.R. 2043 - Nurse Education, Expansion, and Development Act of 2009; Health Reform; Health Workforce Shortage Issues; S. 623/H.R. 1558 - Preexisting Condition Exclusion Patient Protection Act of 2009; (Continued) S. 643/H.R. 1619 - Children's Health Protection Act of 2009; S. 688/H.R. 1691 - Breast Cancer Patient Protection Act; H.R. 2366 - Cancer Drug Coverage Parity Act; FDA Regulation of Opioids; H.R. 2115- Men and Familes Health Care Act; Health Care Reform; H.R. 3962 - Affordable Health Care for America Act; H.R. 3590 - Patient Protection and Affordable Care Act; H.R. 4872 - Reconciliation Act of 2010.

Client expense: Not reported · Firm income: $40,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, White House Office

Issues related to health disparities, health care reform, quality of life, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: H. R. 756 & S. 660, National Pain Care Policy Act; H. R. 1189, Colorectal Cancer Prevention, Early Detection & Treatment Act; S. 717, The 21st Century Cancer Alert Act; proposed Senate national cancer program authorizing legislation; S. 488, the Access to Cancer Clinical Trials Act of 2009; H.R.1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; and the implementation of P.L.111-148, the Patient Protection and Affordable Care Act of 2010..

Client expense: $450,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, White House Office

S.660, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies H.R. 756, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies S.1380, Medicare Payment Advisory Commission (MedPAC) Reform Act, a bill to make the commission an executive branch agency, and provide the Commission new resources and authority to implement Medicare payment policy S.301, Physician Payments Sunshine Act, a bill that would require disclosure of the relationships between physicians and the manufacturers of drugs and devices H.R. 3138, Physician Payments Sunshine Act, a bill that would require disclosure of the relationships between physicians and the manufacturers of drugs and devices H.R. 2502, Comparative Effectiveness Research Act of 2009, a bill to provide for the conduct of comparative effectiveness research for drugs, devices, and other therapies and create a Comparative Effectiveness Research Trust Fund S.1213, Patient-Centered Outcomes Research Act of 2009, a bill to provide for the conduct of comparative effectiveness research for drugs, devices, and other therapies and to establish a Patient-Centered Outcomes Research Trust Fund H.R. 2824, Doctor-Patient Relationship and Research Protection Act, a bill to support federally funded comparative effectiveness research for drugs, devices, and other therapies S.1142, Informed Health Care Decision Making Act, a bill with respect to the inclusion of effectiveness information in drug and device labeling and advertising H.R. 4700, the Transparency in All Health Care Pricing Act of 2010, to provide for transparency in health care pricing H.R. 2249, the Health Care Price Transparency Promotion Act of 2009, to provide for increased price transparency of hospital information and to provide for additional research on consumer information on charges and out-of-pocket costs. H.R. 4803, the Patients Right to Know Act, to ensure health care consumer and provider access to certain health benefits plan information and to amend title XIX of the Social Security Act to provide transparency in hospital price and quality information

Client expense: $480,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Transportation, Dept of (DOT)

Implementation of H.R. 3590, the Patient Protection and Affordable Care Act, to provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. Implementation of H.R. 4872, the Health Care and Reconciliation Act of 2010, a bill that makes a number of health-related financing and revenue changes to the Patient Protection and Affordable Care Act, specifically regarding the medical device tax. S.540, Medical Device Safety Act, a bill that would remove federal preemption protection for certain medical devices H.R.1346, Medical Device Safety Act, a bill that would remove federal preemption protection for certain medical devices Reform of the 510 (k) regulatory pathway H.R. 759, Food and Drug Administration Globalization Act, a bill to improve the safety of food, drugs, devices, and cosmetics S. 882, the Drug and Device Accountability Act, a bill to ensure the safety and quality of medical products and enhance the authorities of the FDA H.R. 2502, Comparative Effectiveness Research Act of 2009, a bill to provide for the conduct of comparative effectiveness research for drugs, devices, and other therapies and create a Comparative Effectiveness Research Trust Fund S.1213, Patient-Centered Outcomes Research Act of 2009, a bill to provide for the conduct of comparative effectiveness research for drugs, devices, and other therapies and to establish a Patient-Centered Outcomes Research Trust Fund H.R. 2824, Doctor-Patient Relationship and Research Protection Act, a bill to support federally funded comparative effectiveness research for drugs, devices, and other therapies S.1142, Informed Health Care Decision Making Act, a bill with respect to the inclusion of effectiveness information in drug and device labeling and advertising H.R. 3090, Health Equity & Accountability Act of 2009, provides for the elimination of racial and ethnic health disparities S.660, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies H.R. 756, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies H.R. 4700, the Transparency in All Health Care Pricing Act of 2010, to provide for transparency in health care pricing H.R. 2249, the Health Care Price Transparency Promotion Act of 2009, to provide for increased price transparency of hospital information and to provide for additional research on consumer information on charges and out-of-pocket costs. H.R. 4803, the Patients Right to Know Act, to ensure health care consumer and provider access to certain health benefits plan information and to amend title XIX of the Social Security Act to provide transparency in hospital price and quality information

Client expense: $480,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Transportation, Dept of (DOT)

H.R.756 and S.660; National Pain Care Policy Act of 2009; Health Care Reform; H.R.3200/S.1679; H.R.3962; H.R.3590; FDA Opioid REMS Policy and Telemedicine.

Client expense: Not reported · Firm income: $50,000

Government targets: Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans. Support Efforts to Eliminate "Lifetime Caps" on health insurance benefits. Support Part D Medicare Coverage Gap Discount Program "draft guidance" to improve the program for beneficiaries. Oppose Recess Appointment of Dr. Donald Berwick as CMS Administrator.

Client expense: Not reported · Firm income: $14,520

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office

H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans.

Client expense: $175,137 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office